Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis

In The Lancet Gastroenterology & Hepatology, Severine Vermeire and colleagues1 report the results from a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension of ABX464 (obefazimod) in patients with moderate-to-severe ulcerative colitis. Patients were randomly assigned to daily oral ABX464 25 mg (n=63), 50 mg (n=63), 100 mg (n=64), or placebo (n=64). At week 8, the modified Mayo Score (MMS) was significantly improved from baseline in all ABX464 dosage groups compared with placebo.